Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | BPTF | Q12830 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416616 | 0.82 | MEN1 (0.66) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL24227649 | 0.81 | ADORA1 (0.63) | MEN1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL3451792 | 0.81 | MEN1 (0.59) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL3220814 | 0.81 | MEN1 (0.59) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL21765569 | 0.81 | MEN1 (0.63) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL782567 | 0.80 | MEN1 (1.00) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL17407824 | 0.79 | HRH4 (0.68) | KMT2AALDH1A1HPGDMAPTTDP1 | |
| SCHEMBL3453164 | 0.79 | BPTF (0.58) | MEN1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL3228721 | 0.78 | MEN1 (0.54) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL3233891 | 0.78 | MEN1 (0.54) | MEN1KMT2AL3MBTL1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| EP-2240021-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097474-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | MEN1 715/4885KMT2A 511/4885L3MBTL1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.